Ryeqo approved for endometriosis, pending PBS subsidy

The Therapeutic Goods Administration has approved Ryeqo, the first new treatment for endometriosis in 13 years. The drug, pending PBS subsidy, costs approximately $135 per month. Endometriosis affects one in seven women and causes symptoms like heavy bleeding and severe pain. Ryeqo, a single-pill alternative, is aimed at managing symptomatic endometriosis by suppressing hormone production. However, its high cost may create an economic burden for patients.